Related Experiment Video
Updated: Jun 23, 2025

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
Investigation of F508del CFTR unfolding and a search for stabilizing small molecules
1University of Manchester, School of Biological Sciences, Oxford Road, Manchester, M13 9PL, UK; The Francis Crick Institute, Cellular Degradation Systems Lab, 1 Midland Road, London, NW1 1AT, UK.
Abstract:
Mutation of phenylalanine at position 508 in the cystic fibrosis transmembrane conductance regulator (F508del CFTR) yields a protein unstable at physiological temperatures that is rapidly degraded in the cell. This mutation is present in about 90% of cystic fibrosis patients, hence there is great interest in compounds reversing its instability. We have previously reported the expression of the mutated protein at low temperature and its purification in detergent. Here we describe the use of the protein to screen compounds present in a library of Federal Drug Administration (FDA) - approved drugs and also in a small natural product library. The kinetics of unfolding of F508del CFTR at 37 °C were probed by the increase in solvent-exposed cysteine residues accessible to a fluorescent reporter molecule. This occurred in a bi-exponential manner with a major (≈60%) component of half-life around 5 min and a minor component of around 60 min. The faster kinetics match those observed for loss of channel activity of F508del CFTR in cells at 37 °C. Most compounds tested had no effect on the fluorescence increase, but some were identified that significantly slowed the kinetics. The general properties of these compounds, and any likely mechanisms for inducing stability in purified CFTR are discussed. These experimental data may be useful for artificial intelligence - aided design of CFTR-specific drugs and in the identification of stabilizing additives for membrane proteins (in general).
Insights
Researchers screened FDA-approved drugs and natural products to find compounds that stabilize the F508del CFTR protein, a key target for cystic fibrosis treatments. Several compounds were identified that significantly slow the protein's unfolding kinetics.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- The F508del mutation in cystic fibrosis transmembrane conductance regulator (CFTR) protein causes instability and rapid degradation, affecting 90% of cystic fibrosis patients.
- Restoring F508del CFTR stability is a major therapeutic goal for cystic fibrosis.
- Previous work involved expressing and purifying the mutated protein at low temperatures.
Purpose of the Study:
- To screen libraries of FDA-approved drugs and natural products for compounds that stabilize the purified F508del CFTR protein.
- To investigate the unfolding kinetics of F508del CFTR at physiological temperatures.
Main Methods:
- Purified F508del CFTR protein was used to screen compound libraries.
- Protein unfolding kinetics were monitored by measuring the accessibility of cysteine residues to a fluorescent reporter at 37°C.
- Bi-exponential unfolding kinetics were observed, with major and minor components.
Main Results:
- Most screened compounds had no effect on F508del CFTR unfolding.
- Several compounds were identified that significantly slowed the unfolding kinetics of the purified protein.
- The observed unfolding kinetics correlate with the loss of channel activity in cellular models.
Conclusions:
- The study identified compounds that can stabilize purified F508del CFTR protein.
- These findings may aid in the rational design of CFTR-specific drugs using AI.
- The results contribute to understanding stabilizing additives for membrane proteins.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
08:59Analysis of Protein Folding, Transport, and Degradation in Living Cells by Radioactive Pulse Chase
Published on: February 12, 2019
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...